DaVita Inc. (NYSE:DVA) Shares Acquired by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of DaVita Inc. (NYSE:DVA) by 295.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 669 shares of the company’s stock after buying an additional 500 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in DaVita were worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wedmont Private Capital boosted its position in shares of DaVita by 4.4% during the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock worth $280,000 after purchasing an additional 75 shares during the period. Blue Trust Inc. boosted its position in shares of DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the period. First Trust Direct Indexing L.P. boosted its position in shares of DaVita by 3.9% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after purchasing an additional 98 shares during the period. Quent Capital LLC boosted its position in shares of DaVita by 21.0% during the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after purchasing an additional 101 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of DaVita by 18.8% during the 1st quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock worth $91,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other news, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Javier Rodriguez sold 32,176 shares of DaVita stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now owns 905,659 shares in the company, valued at $141,219,407.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 173,482 shares of company stock valued at $27,387,069. Insiders own 2.00% of the company’s stock.

DaVita Stock Performance

Shares of DVA stock opened at $164.57 on Wednesday. The stock has a market capitalization of $14.43 billion, a PE ratio of 18.70, a P/E/G ratio of 0.91 and a beta of 0.87. The firm has a 50 day moving average of $155.27 and a two-hundred day moving average of $144.14. DaVita Inc. has a 52 week low of $72.71 and a 52 week high of $167.31. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.47 by $0.12. The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.08 EPS. On average, research analysts predict that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. TD Cowen increased their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Bank of America increased their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. UBS Group raised their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, DaVita currently has an average rating of “Hold” and an average target price of $159.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.